Oral Intake of Specific Bioactive Collagen Peptides Reduces Skin Wrinkles and Increases Dermal Matrix Synthesis

E. Proksch a M. Schunck b V. Zague d D. Segger c J. Degwert c S. Oesser b

a Department of Dermatology, University of Kiel, and b Collagen Research Institute, Kiel, and Skin Investigation and Technology, Hamburg, Germany; c Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

Key Words
Bioactive collagen peptide · Collagen peptides · Skin · Wrinkles · Type I collagen · Elastin · Fibrillin

Abstract
Dietary consumption of food supplements has been found to modulate skin functions and can therefore be useful in the treatment of skin aging. However, there is only a limited number of clinical studies supporting these claims. In this double-blind, placebo-controlled study, the effectiveness of the specific bioactive collagen peptide (BCP) VERISOL® on eye wrinkle formation and stimulation of procollagen I, elastin and fibrillin biosynthesis in the skin was assessed. A hundred and fourteen women aged 45–65 years were randomized to receive 2.5 g of BCP or placebo, once daily for 8 weeks, with 57 subjects being allocated to each treatment group. Skin wrinkles were objectively measured in all subjects, before starting the treatment, after 4 and 8 weeks as well as 4 weeks after the last intake (4-week regression phase). A subgroup was established for suction blister biopsies analyzing procollagen I, elastin and fibrillin at the beginning of the treatment and after 8 weeks of intake. The ingestion of the specific BCP used in this study promoted a statistically significant reduction of eye wrinkle volume (p < 0.05) in comparison to the placebo group after 4 and 8 weeks (20%) of intake. Moreover, a positive long-lasting effect was observed 4 weeks after the last BCP administration (p < 0.05). Additionally, after 8 weeks of intake a statistically significantly higher content of procollagen type I (65%) and elastin (18%) in the BCP-treated volunteers compared to the placebo-treated patients was detected. For fibrillin, a 6% increase could be determined after BCP treatment compared to the placebo, but this effect failed to reach the level of statistical significance. In conclusion, our findings demonstrate that the oral intake of specific bioactive collagen peptides (Verisol®) reduced skin wrinkles and had positive effects on dermal matrix synthesis.

Introduction

Skin appearance and integrity get worse with age due to the synergistic effects of chronological and photoaging, hormonal deficiency and influences of environmental factors [1]. As a consequence of a decline in several metabolic activities, like quantitative and qualitative changes in dermal collagen and elastin, the skin constitution changes and typical symptoms of aging are visible. The loss of connective tissue in cutaneous aging results in de-
creased elasticity, loss of skin tone and a progressive deep-
ening of facial creases and wrinkling [2].

Wrinkles on the face are the most prominent recog-
nized signs of skin aging. Takema et al. [3, 4] reported an
age-related decrease in skin elasticity and a coriaceous ap-
pearance of affected skin areas. Especially facial skin sites
like the corners of the eyes are mostly susceptible to wrin-
kle formation, also popularly known as crow’s feet.

Skin functions and healthy appearance depend on a
sufficient supply of essential nutrients. The relationship
between nutrition and skin has become a hot topic all
over the world. Intervention studies indicate that it is pos-
sible to modulate or delay skin aging and to improve skin
integrity by dietary ingredient supplementation [5].

In preclinical studies it was shown that collagen pep-
tides had stimulatory effects on type I collagen and other
extracellular matrix molecules in human fibroblasts [6,7]. Moreover, in animal studies it was demonstrated that the density and diameter of fibroblasts as well as of col-
lagen fibrils increased by collagen peptide administration
whereas a UVB-induced reduction of type I collagen was
diminished after bioactive collagen peptide (BCP) treat-
ment [8,9].

However, there is no clinical evidence that BCP sup-
plementation may reduce wrinkle formation and benefit
skin metabolism after oral intake in humans. In this study,
we objectively evaluated the efficacy of a specific BCP with
regard to the volume of eye wrinkles after 8 weeks of
daily intake. Moreover, the influence of the BCP treat-
ment on the content of procollagen type I, elastin and fi-
brillin in blister suctions was assessed. To the best of our
knowledge, this is the first double-blind, placebo-con-
trolled study showing that a dietary supplement com-
posed of a specific collagen peptide is effective in reducing
wrinkles and aging-related skin biomarkers.

Material and Methods

Test Product

The test product used in this study was a BCP composed of dif-
ferent specific collagen peptides with a high safety profile derived
from a complex multistep procedure by degradation of porcine
type I collagen. The product was provided by Gelita AG (Eberbach,
Germany), commercially available as Verisol. The product is clear-
ly defined by a matrix-assisted laser desorption ionization mass
spectrometry mass peaks fingerprint with specific collagen pep-
tides of an average molecular weight of 2.0 kD.

Study Design

The study was carried out as a monocentric, double-blind,
randomized, placebo-controlled supplementation study on the
effects of a specific BCP on eye wrinkle volume (primary out-
come) and content of type I procollagen, elastin and fibrillin in
skin fluid (secondary outcomes) after 8 weeks of daily intake.

The study was approved by the Freiburger Ethik-Kommis-


tion with corticoids and/or antihistamines within 4 weeks prior to the start, medication with an anticoagulant, proneness to hyperpigmentation or hypertrophic scar formation, other systemic medication within 4 weeks prior to the start, systemic illness of the subject at the beginning of the study, pregnancy or a period of breastfeeding, immunological disorders, severe disorders within 6 months prior to the start, e.g., cancer, acute cardiac and circulatory disorders, severe diabetes, alcohol and drug abuse, participation in other studies with cosmetic products in the test areas within 2 weeks prior to the start or during the study, participation in a study with a pharmaceutical preparation within 4 weeks prior to the start, intake of nutritional supplements within 4 weeks prior to the start and, except for the test products administered during the study, change in lifestyle or eating habits during the study, treatment with leave-on products, oily or moisturizing skin-cleansing products on the arms, or a change in the usual skin care routine, exposure to intensive sunlight or artificial UV (solarium) light on the test sites within 1 week prior to the start or during the study, swimming, sauna or intensive sport within 1 day prior to measurements, lack of compliance, intellectual or mental inability to follow study instructions.

Assessments

Test Sites

The test sites were the wrinkle area around the left eye (lateral canthus) for eye wrinkle measurements and the inner aspect of the right forearm for the suction blister biopsies used for the subsequent analysis of procollagen type I, elastin and fibrillin.

On every measurement day, the subjects had to expose their uncovered test sites to the indoor climatic conditions (21.5 °C; 50% relative humidity) for at least 30 min.

Measurement Times

There were 4 measurement times for eye wrinkle assessments: immediately before starting the product treatment (t₀), after 4 (t₁) and 8 weeks (t₂) of daily product intake, and 4 weeks after the last intake (t₃, 4-week washout phase).

Suction blisters were generated before starting the treatment (t₀) and after 8 weeks (t₃) of intake.

In each case the subject’s compliance (dosage and way of intake) and tolerance towards the products were checked after 1, 4 and again after 6 weeks of intake.

In vivo Measurement of the Eye Wrinkle Volume

The influence of BCP on the eye wrinkle volume was measured at the outer corner of the eye (lateral canthus) using the optical 3-dimensional in vivo measuring instrument Primos® Compact (GF-Messtechnik GmbH). Three measurements were conducted per test site. The size of the measurement area was 30 × 40 mm². The postbaseline measurements were performed using the overlay function. For each subject, the original pictures of the reference files at the baseline and the corresponding measurement files of the postbaseline measurements were brought into congruence using the 3-dimensional matching function. Height images were computed according to the standard procedure using mathematical filters. These height images were used to calculate the eye wrinkle volumes (in cubic millimeters of one selected wrinkle). After manual marking of the selected eye wrinkles, the volume was computed by the Primos software. This was performed for all 3 images that were taken per test site and measurement point in time. Then, the mean of the 3 single measurements was calculated for each test site and point in time.

Suction Blister Biopsies

To quantify the amount of procollagen I, elastin and fibrillin in the skin of the volunteers before and after treatment with BCP, the so-called suction blister model was applied, according to Kiistala [10]. Per point in time, 2 suction blisters of 7 mm in diameter were generated in the test area. To induce the blisters, Plexiglas suction chambers with 2 circular openings each with a diameter of 7 mm were placed on the test site. A vacuum pressure of about 450–850 mbar was applied. The blisters were induced within 1.5–2.5 h. The liquids of all suction blisters were collected using sterile hypodermic syringes. The liquids were pooled, collected in cryovials at −20 °C and stored frozen at −80 °C immediately after preparation. The small wounds were covered with a wound occlusive and healed completely and scar free within 6–10 days. On completion of the study, the blister fluids were used for the quantitative analysis of procollagen type I, elastin and fibrillin.

Enzyme-Linked Immunosorbent Assays for the Analysis of Procollagen Type I, Elastin and Fibrillin

In vitro enzyme immunoassay kits were used for the quantitative analysis of human procollagen type I (Takara Bio Inc., Japan), human elastin (Cusabio Biotech, China) and human fibrillin-1 (Cusabio Biotech) in the suction blister fluids.

The tests were performed according to the respective instruction manual. Briefly, samples were diluted 1:25 vol/vol with kit sample buffers to reach concentrations within the range of the standards. Every suction blister sample was measured in duplicate. Moreover, the recovery of the enzyme immunoassay kits was analyzed, revealing recovery rates of more than 80% on average.

Statistical Analysis

All data were tested for normal distribution by the 1-sample Kolmogorov-Smirnov test. Statistically significant differences between both treatment groups were analyzed by the 2-sided independent samples t test. The hypothesis of a normal distribution was accepted when there was a p value >0.05. As for the differences between the treatment situations, for a p value <0.05 the difference was accepted as statistically significant.

The following treatment situations for wrinkle volume changes were compared: treatment situations at points in time t₀ (baseline situation), t₁ and t₂ (after 4 weeks and 8 weeks of treatment) and t₃ (4-week washout phase).

The results obtained from the blister suction fluids were expressed in relation to the initial situation and pairwise differences were tested for statistical significance between both treatments.

Results

Subjects and Dropouts

The results of 114 subjects were involved in data analysis. The subjects were between 45.0 and 65.4 years old (55.6 ± 6.0), without statistically significant differences between the treatment group and the placebo group...
A hundred and eight of the 114 subjects finished the study correctly and completely for the eye wrinkle measurements. There were 6 dropouts, none related to the product intake or the study procedure in general.

As for analysis of the suction blister fluids, 40 of the 48 subjects (20 per group) finished the study correctly and completely. The 40 subjects were between 45.8 and 65.0 years of age (55.9 ± 6). There were 8 dropouts, none related to the product intake or the study procedure in general.

No treatment side effects were observed in any of the volunteers.

**Eye Wrinkle Volume**

At the beginning of the study the volume of eye wrinkles between both treatment groups were not statistically significantly different (0.381 ± 0.36 vs. 0.375 ± 0.26 mm$^3$, $p = 0.998$). A hundred and eight of the 114 subjects finished the study correctly and completely for the eye wrinkle measurements. There were 6 dropouts, none related to the product intake or the study procedure in general.

As for analysis of the suction blister fluids, 40 of the 48 subjects (20 per group) finished the study correctly and completely. The 40 subjects were between 45.8 and 65.0 years of age (55.9 ± 6). There were 8 dropouts, none related to the product intake or the study procedure in general.

No treatment side effects were observed in any of the volunteers.

**Eye Wrinkle Volume**

At the beginning of the study the volume of eye wrinkles between both treatment groups were not statistically significantly different (0.381 ± 0.36 vs. 0.375 ± 0.26 mm$^3$, $p = 0.998$).

After 4 weeks of treatment the BCP group showed a statistically significantly reduced eye wrinkle volume of more than 7.2% in comparison to the placebo group ($p < 0.05$). This positive effect was more pronounced after 8 weeks of intake. At this point in time wrinkle volume in the BCP group was significantly ($p < 0.01$) reduced by 20.1% on average (0.326 ± 0.38 vs. 0.408 ± 0.25 mm$^3$) compared to the placebo group (fig. 1a, b). In particular a maximum reduction in eye wrinkle volume of 49.9% was achieved.

Four weeks after the last product intake (4-week regression phase), the BCP treatment group still showed a statistically significant decrease in eye wrinkle volume of 11.5% ($p < 0.01$), as shown in figure 2. It is notable that in the active agent group at the end of the regression phase the same decreased mean eye wrinkle volume (0.326 mm$^3$) was determined as at the end of the treatment period after 8 weeks.

**Blister Suction Fluids**

Due to inhomogeneous data at the beginning of the investigation (prior to treatment) between the drug and the placebo groups the results of procollagen, elastin and fibrillin measurements were expressed in relation to baseline data ($t_0$).

**Procollagen Content**

Procollagen type I content was increased by 65% after 8 weeks of BCP treatment compared to the placebo group. This pronounced impact on collagen synthesis was statistically significant ($p < 0.01$; fig. 3).

**Table 1.** Demographic data on the study subjects

<table>
<thead>
<tr>
<th>Group</th>
<th>Baseline ($t_0$)</th>
<th>4 weeks ($t_1$)</th>
<th>8 weeks ($t_2$)</th>
<th>4-week regression ($t_3$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>57</td>
<td>55</td>
<td>55</td>
<td>52</td>
</tr>
<tr>
<td>B</td>
<td>57</td>
<td>55</td>
<td>55</td>
<td>55</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Subject number</th>
<th>A</th>
<th>B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age ± SD, years</td>
<td>55.6±5.5</td>
<td>55.6±5.6</td>
</tr>
<tr>
<td>A</td>
<td>55.4±5.7</td>
<td>55.4±5.7</td>
</tr>
<tr>
<td>B</td>
<td>55.4±5.7</td>
<td>55.4±5.5</td>
</tr>
</tbody>
</table>

**Fig. 1.** a Orally administered BCP led to a statistically significant reduction of eye wrinkle volume after 4 and 8 weeks of treatment. Over the same period of time, eye wrinkle volume in the placebo-treated group increased continuously (mean ± SEM; $n = 57$; * $p < 0.05$, ** $p < 0.01$). b Visible reduction of eye wrinkle volume after 8 weeks of BCP intake. Exemplary pictures of 2 participants of the active agent group before (left) and after (right) treatment.

**Fig. 2.** Reduction of eye wrinkle volume persisted in BCP-treated volunteers 4 weeks after last intake (mean ± SEM; $n = 57$; ** $p < 0.01$).
Elastin Content
In addition to procollagen, BCP intake also promoted a statistically significant (p < 0.01) increase in elastin content of 18% in comparison to the placebo treatment after 8 weeks (fig. 3).

Fibrillin Content
Ingestion of BCP led to a clear increase in fibrillin content of 6% in comparison to placebo after 8 weeks of treatment but this result failed to reach the level of statistical significance (fig. 3).

Discussion
Throughout our life skin integrity changes and shows a decrease in elasticity and moisture, as well as a noticeable increase in wrinkles. Skin wrinkle formation is the most prominent sign of growing old [1, 2] and seems to be more common in the skin of Caucasian people [11]. In a prospective study it was found that wrinkle onset was delayed by about 10 years in Chinese women compared with French women [12].

Independently of wrinkle incidence and skin ethnic aspects, concerns about changes in physical appearance brought on by aging are very common. As the demand for interventions to ameliorate visible signs of aging is continuously growing [13], interest in the development of dietary supplements and functional food products for skin health has increased as well.

In preclinical and clinical studies food supplements have been considered as effective cosmeceutical substances with a potential for reducing wrinkles and improving skin appearance. Especially the efficacy of orally administered collagen peptides on skin health has been demonstrated in several investigations [14–17].

The current study is the first investigating the efficacy of a specific, orally administered BCP (Verisol®) on eye wrinkles, demonstrating a statistically significant reduction of eye wrinkle deepness (crow’s feet) in comparison to a placebo treatment. At the end of the treatment after 8 weeks the eye wrinkle volume in the verum group had decreased by 17.7% compared to the baseline, whereas in the placebo group in the same time period the wrinkle volume had increased by 14.5% (Δ 32.2%).

The observed changes in the placebo group might have been caused by altered weather and climatic conditions during the study period. It is most unlikely that the determined effect is caused by diet-related alterations, as the subjects were instructed not to modify their lifestyle during the study period. In addition, a direct impact of the placebo can be excluded as no influence of maltodextrin on skin physiology has been described in the literature. Therefore it can be assumed that the variations in the placebo group do not refer to systematic effects.

Apart from the observed efficacy of an oral Verisol® treatment, it is striking that the positive effect on skin health was persistent for at least 4 weeks after having stopped the BCP intake. A possible explanation for this long-lasting improvement might be the pronounced increase in the biosynthesis of essential dermal macromolecules such as collagen, elastin and fibrillin. It is known that collagen and elastin are the major components in the dermis supporting preservation of skin structure, skin firmness and elasticity, and that they directly affect wrinkle formation. In contrast to the healthy skin situation, an alteration of elastic fibers and degradation of collagen bundles does occur in the dermis of wrinkled skin. It is known that collagen fiber deficiencies in aged and photodamaged human skin are a major cause of skin wrinkling.

Apart from the visible changes in skin wrinkles, in the current study the synthesis of these dermal extracellular matrix proteins which are crucial for skin health and well-being was investigated in suction blister fluids. It was demonstrated that at the end of the treatment period the collagen content was increased 1.65-fold and that the amount of elastin was increased 1.2-fold after Verisol treatment, compared to the placebo group.

In addition to these positive impacts the ingestion of BCPs led to an increase of 6% in the content of fibrillin in comparison to placebo, by the end of the study period. Fibrillins are the most important components of microfibrils and are necessary for the integrity of elastic fiber bundles described by Lee et al. [15], who observed a re-

[Figure 3: The amount of procollagen type I and elastin was statistically significantly increased 8 weeks after BCP administration, in contrast to placebo treatment. The content of fibrillin in suction blister fluid was increased after 8 weeks of BCP ingestion by trend (mean ± SEM; n = 20; * p < 0.05).]
duced fibrillin-1 expression in wrinkled skin, which demonstrated the important role of fibrillin for skin functionality. Fibrillin connects elastic fibers with small leucine-rich proteoglycans (like decorin and biglycan) which are essential for the water-binding capacity in connective tissues [18].

Overall, BCP treatment seems to have a positive impact on important dermal macromolecules [19] which have a direct influence on skin wrinkle formation. Our current findings confirm previous reports from experimental and animal trials demonstrating the stimulatory effects of collagen peptides on anabolic processes supporting the maintenance of the dermis extracellular matrix [6–9, 20]. Our in vitro studies on primary human dermal fibroblasts demonstrated a stimulatory effect of Verisol® on the expression of skin extracellular matrix macromolecules. After supplementation of the specific collagen peptides we were able to demonstrate a pronounced, statistically significant increase in type I collagen expression as well as proteoglycan expression, such as biglycan, decorin and versican (data not published).

Apart from these positive influences of Verisol® for dermal matrix synthesis it has been described that the daily intake of collagen peptides decreases expression levels of matrix metalloproteinase-2, a catabolic enzyme which is, for instance, responsible for collagen type IV breakdown [7].

Type IV collagen forms a highly cross-linked network essential for mechanical stability of the basement membrane and is therefore an important factor for skin wrinkles and furrow formation [21]. The observed stimulatory impact on the dermal matrix of specific BCPs, as well as the reported anticaotic effect, suggest a possible mechanism for explaining the significant wrinkle reduction demonstrated by the Verisol® treatment.

Another factor that promotes wrinkle formation is decreased skin elasticity, as shown by Fujimura et al. [22]. Skin elasticity is influenced by several parameters, like elastic fiber formation and skin moisture. In a previous study we investigated the effects of daily Verisol® ingestion in 35- to 55-year-old female volunteers on skin elasticity and other skin wrinkle-related parameters. In a double-blind, randomized, placebo-controlled clinical study, skin elasticity was significantly improved in women who received 2.5 g/day of a specific BCP for 8 weeks. In addition, the results revealed that the observed positive effects of BCP administration were more pronounced in women who were over 50 years old, as indicated by increased skin hydration and improved skin elasticity [23].

Conclusions

Based on the results of the study, it can be concluded that the oral ingestion of specific collagen peptides led to a pronounced, statistically significant reduction of eye wrinkle volume. In contrast to most topicaly applied substances this positive effect on the skin seems to be caused by a direct impact on dermal extracellular matrix turnover, as demonstrated by a significant increase in collagen and elastin synthesis. The direct effect on the dermal matrix might explain the long-lasting improvement of skin wrinkles for at least 4 weeks after the end of the supplementation of the collagen peptides. It has to be pointed out that the results presented are only valid for the specific collagen peptide composition (Verisol®) used in this study. Other collagen hydrolysates or collagen peptides might exhibit dissenting effects. Here further research especially into the mode of action of BCPs on dermal structures would be desirable.

References